Pharmacological Management of Large Intestine Neoplastic Diseases

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorCho , Seungwoo
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentDrimba, László
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.date.accessioned2024-05-24T09:29:38Z
dc.date.available2024-05-24T09:29:38Z
dc.date.created2024-02-26
dc.description.abstractThrough this thesis, various types of large intestine neoplastic diseases were discussed in their pathophysiology, epidemiology, risk and protective factors, clinical presentations, diagnosis, screening and prognosis, and most crucially their’ therapeutic management. Although surgical resection is most recommended for stage I CRC, adjuvant chemotherapy is advised for patients at intermediate and high risk. De Gramont regimen of LV5FU2 is the optimal treatment for intermediate risk patients with microsatellite stability. Stage II high-risk or stage III CRC patients require FOLFOX or CAPOX treatment regimens as the current therapeutic strategy. Also, clinical trials from IDEA revealed that at stage II high-risk CRC patients, non-inferiority DFS of three months of CAPOX treatment to six months was proven. On the other hand, inferiority DFS of three months of FOLFOX treatment compared to six months was revealed. In this term, three months of CAPOX treatment was favored over six months of treatment as it induces reduced side effects of sensory peripheral neuropathy. Therefore, it leaves a vital responsibility of the clinicians to determine the best eligible chemotherapy regimen and its duration to maximize the DFS and minimize the following side effects. Lastly, novel pharmacological treatments using immunotherapies were discussed.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent48
dc.identifier.urihttps://hdl.handle.net/2437/370293
dc.language.isoen
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectLarge
dc.subjectIntestine
dc.subjectNeoplastic
dc.subjectDiseases
dc.subjectPharmacological
dc.subjectManagement
dc.subject.dspaceMedicine::Pharmacology
dc.titlePharmacological Management of Large Intestine Neoplastic Diseases
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
Cho Seungwoo_MD Thesis_Pharmacological Management of Large Intestine Neoplastic Diseases-final upload.pdf
Méret:
1.98 MB
Formátum:
Adobe Portable Document Format
Leírás:
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Medicine)